Novogenia AG (ticker symbol: 7V0, formerly Darwin AG), an international healthcare company focused on human genetics and personalized products, has published its issuer report for the first half of 2026. The report reveals a mixed financial performance but underscores significant strategic strides that position the company for future growth in the expanding personalized prevention and healthcare market. As detailed in the release on NEWMEDIAWIRE, the company reported consolidated revenue of EUR 25.7 million, a 7% decline from the prior-year period, primarily due to lower volumes in the pharmaceutical and medical device trading segment caused by regulatory changes. However, the DNA analysis and personalized products segment posted positive revenue growth, highlighting the resilience of Novogenia's core business.
CEO Dr. Daniel Wallerstorfer commented, “The financial performance in the first half of 2026 did not meet our expectations in all business areas. Thus, we have not yet been able to realize our ambitious growth plans. However, we are encouraged by the positive year-on-year development of our core business in DNA analyses and personalized health products, as well as by a significant reduction in our cost base.” This optimism is supported by the company's cost-saving measures, which improved operating profit by approximately EUR 2.7 million, although EBIT remained negative at EUR -4.7 million, a 4.1% improvement from the prior year. Net income was -EUR 2.1 million, compared to a positive EUR 2.0 million in the previous year, which had benefited from a higher financial result.
Despite the revenue decline, Novogenia maintains a solid financial position with EUR 39.8 million in cash and cash equivalents as of June 30, 2026, down from EUR 71.9 million the previous year. This liquidity provides a foundation to drive further development. The company made notable strategic progress in H1 2026, including expanding its collaboration with 10X Health Systems, launching the enhanced Methylation Test MGT Plus in the U.S., and advancing preparations with G42 in Abu Dhabi for a Middle East market launch, including Halal certification. Additionally, Novogenia launched the Multi-Cancer Check, introduced a new software platform for its NovoDaily product line, and commenced construction of a new company site in Hallwang near Salzburg, set for completion in early 2028.
The renaming from Darwin AG to Novogenia AG, approved at the 2026 Annual General Meeting, was implemented in July 2026, consolidating brand identity and streamlining communication. To further engage investors, Novogenia representatives will participate in several upcoming conferences, including the 5th Zurich Investor Day on September 29, 2026, the Abu Dhabi Future Health Summit from October 20–22, 2026, the ODDO BHF Autumn Round Table on October 22, 2026, and the Deutsches Eigenkapitalforum from November 23–25, 2026. These engagements demonstrate the company's commitment to transparency and strategic outreach.
Looking ahead, Novogenia aims to mitigate the impact of changes to digital platform algorithms on its sales channels and continue reducing costs. The company's focus on personalized prevention and healthcare positions it well in a growing market. For more information, visit https://novogenia.com/novogenia-ag. The original release can be viewed on www.newmediawire.com.
